RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Humacyte, a pioneering biotechnology firm, announced today that Humacyte founder, Laura Niklason, M.D., Ph.D., will be a keynote speaker at the 9th Annual Stem Cell Meeting on the Mesa presented by the Alliance for Regenerative Medicine (ARM).
The Stem Cell Meeting on the Mesa is a three-day conference that brings together senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures.
The conference will take place in La Jolla, California from October 7th to October 9th. Dr. Niklason’s presentation will take place on October 9th at 8:15 AM PT.
Dr. Niklason is a Professor at Yale University in Biomedical Engineering and Anesthesia, and also serves as Vice-Chair for Anesthesia at Yale. She is a recognized world leader in the development of engineered therapies and regenerative medicine, will speak about off-the-shelf, bioengineered arteries. Humacyte, the North Carolina-based company that Dr. Niklason helped to create, develops novel human tissue-based investigational products intended to meet the critical needs of patients requiring life-saving, vascular surgery.
“We are honored to have Dr. Laura Niklason as the keynote speaker at this event,” said Jennifer Braswell, Executive Director of the Sanford Stem Cell Clinical Center at the University of California at San Diego. “This year’s Stem Cell Meeting on the Mesa has one of the most impressive speaking rosters we’ve ever had, and Dr. Niklason is an excellent addition.”
For more information about the 9th annual Stem Cell Meeting, please click here.
Humacyte, Inc., a privately held company founded in 2005, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix based tissues that are designed be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for a variety of patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to result in off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.